Background Treatment of newly diagnosed advanced-stage ovarian cancer typically involves
cytoreductive surgery and systemic chemotherapy. We conducted a trial to investigate …

… Author links open overlay panel SN Koole a b c 1 , JM Kieffer d 1 , K.Sikorska e , JH Schagen
van Leeuwen f , HWR Schreuder g , RH Hermans h , IH de Hingh i j , J. van der Velden c k , …

… van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in …
van Driel WJ, Koole SN, Sonke GS. Hyperthermic intraperitoneal chemotherapy in ovarian …

Background The OVHIPEC-1 trial previously showed that the addition of hyperthermic
intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery resulted in improved …

The pharmaceutical value chain, including clinical trials, pricing, access, and reimbursement,
is designed for classical monotherapies. Although there has been a paradigm shift that …

PURPOSE In the randomized open-label phase III OVHIPEC trial, the addition of hyperthermic
intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery (CRS) improved …

… III OVHIPEC trial - Koole - 2022 - … SN Koole entitled “HIPEC for ovarian cancer”,
previously published limitedly on paper, and at https://www.publicatie-online.nl/publicaties/simone-koole…

Simple Summary Many cancer survivors have difficulties in attaining and maintaining
physical activity (PA) after treatment. Therefore, we developed an Internet-based PA support …

… Ubachs and Koole wrote the initial drafts of the manuscript and performed the analyses. Dr.
… Bruijs, Koole and Ubachs were responsible for data collection. Dr. Schagen van Leeuwen, …

The extent of peritoneal metastases (PM) largely determines the possibility of complete or
optimal cytoreductive surgery in advanced ovarian cancer. An objective scoring system to …